Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ALMS

Alumis Inc. Common Stock

Healthcare | Biotechnology

No licensed closing price on file for ALMS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.66

Alumis Inc. Common Stock (NASDAQ: ALMS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 04:43 UTC.

What Alumis Inc. Common Stock does

Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases as alternatives to broad immunosuppression. The company's primary programs center on two Tyrosine Kinase 2 inhibitors: envudeucitinib, currently in Phase 3 trials for plaque psoriasis with an expected FDA application submission, and A-005, a central nervous system-penetrant inhibitor in early development. Through a recent acquisition, Alumis also obtained lonigutamab, a monoclonal antibody for potential thyroid eye disease treatment.

Summarized from Alumis Inc. Common Stock’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.66

Charts

Charts are in the appInteractive charts for ALMS are available in Oxford Ledge.
Open ALMS in Oxford Ledge →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-09
  • 2026-09-09DirectorPurchase273,290$2.90M
  • 2026-09-09DirectorSale-48,065$507.0K
  • 2026-09-09DirectorPurchase220,070$2.46M
Sign in to see all transactions →

Company news

View all →

Questions this page answers

What does Alumis Inc. Common Stock do?

Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases as alternatives to broad immunosuppression.

When did ALMS last file with the SEC?

Alumis Inc. Common Stock's most recent SEC filing on record is a 8-K filed 2026-07-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 04:43 UTC. This page is also available as JSON at /api/data?ticker=ALMS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ALMS and 5,000+ tickers.

Create a free account — keep ALMS
For your agent
GET /api/data?ticker=ALMS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt